SCHEMBL2153176

SCHEMBL2153176

COc1cccc(-c2c(Cl)sc3c2C(=O)C(C)(c2ccc(C)cc2)C(=O)N3)c1

nearest known ligand 0.45

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 12/20 0.45
PGR P06401 1/20 0.38
ALKBH3 Q96Q83 1/20 0.36
ACLY P53396 1/20 0.36
GRIN1 Q05586 2/20 0.35
GRIN2A Q12879 2/20 0.35
GRIN2D O15399 1/20 0.35
GRIN3B O60391 1/20 0.35
GRIN2B Q13224 1/20 0.35
GRIN2C Q14957 1/20 0.35
GRIN3A Q8TCU5 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2153121 0.94 HTR6 (0.52) HTR6PGRGRIN1GRIN2AGRIN2D
SCHEMBL2159541 0.92 HTR6 (0.41) HTR6PGRALKBH3ACLY
SCHEMBL2153219 0.92 HTR6 (0.54) HTR6PGRGRIN1GRIN2AGRIN2D
SCHEMBL2153269 0.91 HTR6 (0.44) HTR6PGRGRIN1GRIN2A
SCHEMBL2153856 0.91 HTR6 (0.43) HTR6PGRACLYGRIN1GRIN2A
SCHEMBL14718531 0.91 HTR6 (0.47) HTR6PGRGRIN1GRIN2AGRIN2D
SCHEMBL13570727 0.90 HTR6 (0.50) HTR6
SCHEMBL2153166 0.90 HTR6 (0.44) HTR6PGRALKBH3
SCHEMBL2154223 0.89 HTR6 (0.43) HTR6PGRACLY
SCHEMBL2153359 0.88 HTR6 (0.40) HTR6GRIN1GRIN2AGRIN2DGRIN3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2519527-B1 THIENO[2,3-B]PYRIDINEDIONE ACTIVATORS OF AMPK AND THERAPEUTIC USES THEREOF POXEL (FR) 2013-12-18 EP claimed
US-20130053401-A1 THIENO [2,3-B] PYRIDINEDIONE ACTIVATORS OF AMPK AND THERAPEUTIC USES THEREOF POXEL (FR) 2013-02-28 US claimed
EP-2519527-A1 THIENO [2,3-B]PYRIDINEDIONE ACTIVATORS OF AMPK AND THERAPEUTIC USES THEREOF Poxel (FR) 2012-11-07 EP claimed
US-9365584-B2 Thieno [2,3-B] pyridinedione activators of AMPK and therapeutic uses thereof POXEL (FR) 2016-06-14 US disclosed
EP-2519527-B1 THIENO[2,3-B]PYRIDINEDIONE ACTIVATORS OF AMPK AND THERAPEUTIC USES THEREOF POXEL (FR) 2013-12-18 EP disclosed
US-20130053401-A1 THIENO [2,3-B] PYRIDINEDIONE ACTIVATORS OF AMPK AND THERAPEUTIC USES THEREOF POXEL (FR) 2013-02-28 US disclosed
EP-2519527-A1 THIENO [2,3-B]PYRIDINEDIONE ACTIVATORS OF AMPK AND THERAPEUTIC USES THEREOF Poxel (FR) 2012-11-07 EP disclosed
WO-2011080277-A1 THIENO [2,3-B] PYRIDINEDIONE ACTIVATORS OF AMPK AND THERAPEUTIC USES THEREOF POXEL (FR) 2011-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130053401-A1 THIENO [2,3-B] PYRIDINEDIONE ACTIVATORS OF AMPK AND THERAPEUTIC USES THEREOF PRKAB1, PRKAG1, PRKAB2 HTR6 2378/4885PGR 2658/4885ALKBH3 2201/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.